Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SK Biopharmaceuticals Co., Ltd. (326030.KS)
Seongnam-si, KR
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.06% | +4.27% | +4.16% | -9.52% | -19.72% | -16.52% | +15.93% | +42.70% | -4.56% | -19.21% | -19.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 7 | -1 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+29.1% ★ Q1'26: +57.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+11.1% Q1'26: +351.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+39.1% ★ Q1'26: +36.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+28.9% ★ Q1'26: +39.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+36.1% ★ Q1'26: +63.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -2.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.22× ★ Q1'26: 0.14× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 11 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 4 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.00B
est: 31.66B (-17.9%)
|
418.64B
est: 249.84B (+67.6%)
|
246.18B
est: 251.27B (-2.0%)
|
354.89B
est: 333.82B (+6.3%)
|
547.60B
est: 533.50B (+2.6%)
|
706.74B
est: 707.65B (-0.1%)
|
935.23B
924.58B – 941.43B
+32.2% YoY
|
1.13T
953.87B – 1.25T
+21.4% YoY
|
1.31T
1.19T – 1.38T
+15.0% YoY
|
1.17T
1.06T – 1.24T
-10.4% YoY
|
| EBITDA |
-224.59B
est: -7.15B (-3,040.6%)
|
167.68B
est: -56.44B (+397.1%)
|
-125.77B
est: -56.76B (-121.6%)
|
-8.73B
est: -75.41B (+88.4%)
|
100.71B
est: 38.57B (+161.1%)
|
220.89B
est: 51.16B (+331.7%)
|
67.62B
66.85B – 68.07B
+32.2% YoY
|
82.06B
68.97B – 90.67B
+21.4% YoY
|
94.37B
85.82B – 99.97B
+15.0% YoY
|
84.52B
76.86B – 89.53B
-10.4% YoY
|
| EBIT |
-235.45B
est: -8.14B (-2,793.9%)
|
156.04B
est: -64.21B (+343.0%)
|
-138.75B
est: -64.57B (-114.9%)
|
-24.04B
est: -85.79B (+72.0%)
|
83.28B
est: 19.42B (+328.9%)
|
203.94B
est: 25.76B (+691.8%)
|
34.04B
33.65B – 34.27B
+32.2% YoY
|
41.31B
34.72B – 45.65B
+21.4% YoY
|
47.51B
43.20B – 50.33B
+15.0% YoY
|
42.55B
38.69B – 45.07B
-10.4% YoY
|
| Net Income |
-247.41B
est: -235.22B (-5.2%)
|
64.85B
est: -13.88B (+567.3%)
|
-139.43B
est: -120.03B (-16.2%)
|
-32.88B
est: -45.16B (+27.2%)
|
240.74B
est: 67.78B (+255.2%)
|
266.95B
est: 169.64B (+57.4%)
|
278.44B
248.97B – 382.71B
+64.1% YoY
|
366.50B
316.12B – 447.62B
+31.6% YoY
|
479.51B
423.01B – 516.45B
+30.8% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
79.10B
est: 26.65B (+196.8%)
|
89.80B
est: 210.35B (-57.3%)
|
112.32B
est: 211.55B (-46.9%)
|
204.31B
est: 281.06B (-27.3%)
|
114.79B
est: 177.45B (-35.3%)
|
146.29B
est: 235.38B (-37.8%)
|
311.07B
307.53B – 313.13B
+32.2% YoY
|
377.49B
317.27B – 417.14B
+21.4% YoY
|
434.16B
394.81B – 459.90B
+15.0% YoY
|
388.83B
353.59B – 411.87B
-10.4% YoY
|
| EPS |
-3,447.52
est: -3,003.58 (-14.8%)
|
828.03
est: -177.20 (+567.3%)
|
-1,780.43
est: -1,532.64 (-16.2%)
|
-419.89
est: -576.70 (+27.2%)
|
3,066.97
est: 865.52 (+254.3%)
|
3,408.75
est: 2,166.13 (+57.4%)
|
3,555.46
3,179.19 – 4,886.94
+64.1% YoY
|
4,679.98
4,036.64 – 5,715.84
+31.6% YoY
|
6,122.94
5,401.50 – 6,594.73
+30.8% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dong Hoon Lee | Chief Executive Officer, President & Executive Director | 1B | male |
| Jiyoung Jung | Chief Financial Officer & Executive Director | — | male |
| Seon-kwan Hwang | Chief Technology Officer | — | — |
| Yong-Je Shin | Director of RPT Preclinical Center | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 326030.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
